Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial.

OBJECTIVE: To study whether recombinant human erythropoietin (r-hu-Epo) improves anaemia and reduces disease activity in patients with rheumatoid arthritis and anaemia of chronic disease (ACD). METHODS: A 52 week placebo controlled randomised double blind trial with r-hu-Epo was performed in 70 pati...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Rheum Dis
Päätekijät: Peeters, H R, Jongen-Lavrencic, M, Vreugdenhil, G, Swaak, A J
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 1996
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC1010292/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8984939/
https://ncbi.nlm.nih.govhttps://doi.org/10.1136/ard.55.10.739
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia